From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Characteristic | Value |
---|---|

Age (years) (n = 575) | |

Mean ± SD | 57 ± 13 |

Median | 58 |

Range | 19 -99 |

Sex | |

Female, N (%) | 419 (72.9%) |

Male, N (%) | 156 (27.1%) |

Age at diagnosis (years) (n = 564) | |

Mean ± SD | 46.2 ± 13.6 |

Median | 47 |

Range | 5-81 |

Duration of disease (years) (n = 564) | |

Mean ± SD | 10.3 ± 9.4 |

Median | 8 |

Range | 0-53 |

HAQ index at screening (n = 573) | |

Mean ± SD | 56.1 ± 15.4 |

Median | 55 |

Range | 2-98 |

Swollen joint count at screening (n = 568) | |

Mean ± SD | 16.3 ± 7.5 |

Median | 14 |

Range | 0-49 |

MTX doses in mg/week (n = 425) | |

Mean ± SD | 14.5 ± 3.0 |

Median | 15 |

Range | 5-25 |

MTX use | |

Yes, N (%) | 537 (93.4%) |

No, N (%) | 14 (2.4%) |

Unknown, N (%) | 24 (4.2%) |

NSAID use | |

Yes, N (%) | 414 (72%) |

No, N (%) | 46 (8%) |

Unknown, N (%) | 115 (20%) |

Corticosteroid use | |

Yes, N (%) | 341 (59.3%) |

No, N (%) | 84 (14.6%) |

Unknown, N (%) | 150 (26.1%) |